Brought to you by 
Angiotech to spin off part of API division; cancelled
26 Mar 2013
Executive Summary
Angiotech Pharmaceuticals (implantable devices and treatments for acute injuries) will spin off into a new company--Angiotech Pharmaceutical Interventions (API)--its business assets that are outside the IP and royalty revenue related to the Taxus coronary stent system.
Deal Industry
- Medical Devices
- Pharmaceuticals
-
Medical Devices
- Implantable Devices
-
Surgical Equipment & Devices
- Minimally or Less Invasive
Deal Status
- Withdrawn
Deal Type
-
Financing
- Convertible Debt
- Private Placement
- Spin-Off
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Angiotech to spin off part of API division; cancelled
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice